Segment Information (Tables)

9 Months Ended

Mar. 31, 2014

Segment Reporting [Abstract]

Revenue by Reportable Segment

The following tables present revenue for each reportable segment and Corporate:

	Three Months Ended March 31
(in millions)	2014		2013
Pharmaceutical (1)	$	18,762	$	22,070
Medical	2,657		2,484
Total segment revenue	21,419		24,554
Corporate (2)	8		(2		)
Total revenue	$	21,427	$	24,552

	Nine Months Ended March 31
(in millions)	2014		2013
Pharmaceutical (1)	$	60,018	$	68,314
Medical	8,168		7,363
Total segment revenue	68,186		75,677
Corporate (2)	4		(4		)
Total revenue	$	68,190	$	75,673

(1) The decrease in Pharmaceutical segment revenue is primarily due to the Walgreens contract expiration.

(2) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Segment Profit by Reportable Segment

The following tables present segment profit by reportable segment and Corporate:

	Three Months Ended March 31
(in millions)	2014			2013
Pharmaceutical	$	452		$	498
Medical	111			100
Total segment profit	563			598
Corporate	(55		)	(123		)
Total operating earnings	$	508		$	475

	Nine Months Ended March 31
(in millions)	2014			2013
Pharmaceutical	$	1,368		$	1,339
Medical	348			268
Total segment profit	1,716			1,607
Corporate	(218		)	(168		)
Total operating earnings	$	1,498		$	1,439

Assets by Reportable Segments

The following table presents total assets for each reportable segment and Corporate:

(in millions)	March 31, 2014		June 30, 2013
Pharmaceutical (1)	$	14,447	$	16,258
Medical	6,376		6,521
Corporate	3,878		3,040
Total assets	$	24,701	$	25,819

(1) The decrease in Pharmaceutical segment assets is primarily due to the Walgreens contract expiration.